Loading...
•
Sep 30, 2020
Esperion Q3 2020 Earnings Report
Esperion reported financial results for Q3 2020 and provided a business update.
Key Takeaways
Esperion's Q3 2020 total revenue was $3.8 million, including $3.3 million from net product sales and $0.5 million from partner reimbursement. The company's net loss was $85.4 million, or $3.07 per share.
Quarter-over-quarter script growth exceeded 500 percent for NEXLETOL and NEXLIZET.
U.S. product revenue increased five-fold during the third quarter.
Daiichi Sankyo Europe launched NILEMDO and NUSTENDI in Germany.
NEXLETOL and NEXLIZET are now included in the American Association for Clinical Endocrinologists’ updated lipid guidelines.
Esperion
Esperion
Esperion Revenue by Segment
Revenue by Segment
U.S. Net Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Esperion expects that current cash resources, coupled with future revenue from NEXLETOL and NEXLIZET commercial net product sales are sufficient to fund continued operations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income